Eosinophilic Biomarker Found for Aggressive IBD
|
By LabMedica International staff writers Posted on 14 Dec 2017 |
|
Image: Peripheral bloods smear showing five eosinophils, from a patient with eosinophilia (Photo courtesy of the Hospital for Sick Children, Toronto).
Peripheral blood eosinophilia (PBE) in inflammatory bowel disease is associated with ulcerative colitis (UC) and active disease. Little data exist on the long-term impact of PBE on disease course.
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Automatic CLIA Analyzer
Shine i6000
New
POC Immunoassay Analyzer
Procise DX
Latest Pathology News
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read more
Molecular Diagnostics
view channel
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Earlier prognostic information could improve triage and guide treatment... Read more
Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale.... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more
Microbiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more
Industry
view channel
FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
Endocrine therapy resistance remains a significant challenge in estrogen receptor–positive, human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer, where tumor evolution can limit... Read more
